Latest Earnings Results: Q3 '26
Estimated EPS
-$0.54
Reported EPS
---
Surprise
---
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Tvardi Therapeutics, Inc. reported a net loss of $6.5 million for the three months ended June 30, 2026, with cash and cash equivalents totaling $15.8 million as of that date.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -- | -$0.78 | -- | N/A |
Q3 '26 | -$0.54 | -- | -- | N/A |
Q2 '26 | -$0.65 | -$0.69 | -5.35% | MISSED |
Q1 '26 | -$0.74 | -$0.73 | 1.92% | BEAT |
Q4 '25 | -$0.65 | -$0.78 | -20.70% | MISSED |